Roche receives FDA approval for first companion diagnostic to identify endometrial cancer patients eligible for immunotherapy
The Pharma Data
MAY 18, 2021
Food and Drug Administration (FDA) approval of the VENTANA MMR RxDx Panel for advanced or recurrent endometrial cancer patients. Testing can identify patients eligible for treatment with JEMPERLI (dostarlimab-gxly) monotherapy, an anti-PD1 immunotherapy from GlaxoSmithKline (GSK) that was approved by the FDA on 22 April 2021.
Let's personalize your content